metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced - colorectal cancer (mCRC) metastatic/advanced - colorectal cancer (mCRC)
versus Standard of Care (SoC)
	atezolizumab plus cometinib
	Modul Cohort 4, 2023 European Journal of Cancer NCT02291289	RCT	metastatic/advanced - colorectal cancer (mCRC)	atezolizumab plus cobimetinib	fluoropyrimidine plus bevacizumab in 2- or 3-week treatment cycles depending on the fluoropyrimidine used	Patients 18 years of age or older with histologically confirmed, measurable, unresectable mCRC	65 / 34	some concern	inconclusive	inconclusive 44 % increase in progression or deaths (PFS) (PE) Cobimetinib plus atezolizumab had an unfavourable benefit:risk ratio in HER2‒/MSS/BRAFwt mCRC.
	atezolizumab plus SoC
	Modul Cohort 2, 2022 J Cancer Res Clin Oncol 2018;: ESMO Oct 2022 NCT02291289	RCT	metastatic/advanced - colorectal cancer (mCRC)	Atezolizumab plus control	FP (fluoropyrimidine) based chemotherapy plus bevacizumab	Patients 18 y and older with histologically confirmed, measurable, unresectable, previously untreated mCRC, an ECOG PS <= 2, and >=16 weeks of life expectancy at the time of study entry	297 / 148	low	inconclusive	inconclusive 8 % decrease in progression or deaths (PFS) (PE)
mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)
versus Bevacizumab plus FOLFOXIRI
	atezolizumab plus FOLFOXIRI plus bevacizumab
	AtezoTRIBE, 2022 BMC Cancer 2020 Jul 22;20(1):683. The Lancet Onc. July 2022 ASCO May 2023 NCT03721653	RCT	mCRC - 1st line (L1)	atezolizumab plus FOLFOXIRI plus bevacizumab	FOLFOXIRI plus bevacizumab	Patients aged 18–75 years, with ECOG PS ≤2 if aged < 70 years, or ECOG PS 0 if aged 71–75 years	145 / 73	some concern	suggested	suggested 30 % decrease in progression or deaths (PFS) (PE) 1) The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer2) Pts with IS IC-high and/or TMB high pMMR mCRC seem to derive a survival benefit from adding atezo to FOLFOXIRI/bev as upfront treatment.
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus capecitabine, placebo plus bevacizumab
	atezolizumab plus bevacizumab
	BACCI, 2022 JAMA Netw Open 2022; 5:e2149040-. NCT02873195	RCT	mCRC - 2nd line (L2)	capecitabine plus bevacizumab plus atezolizumab	capecitabine plus bevacizumab plus placebo	Patients 18 years and older with Refractory Metastatic Colorectal Cancer	82 / 46	low	inconclusive	inconclusive 27 % decrease in progression or deaths (PFS) (PE) In this randomized clinical trial, the addition of atezolizumab to capecitabine and bevacizumab therapy provided limited (ie, not clinically meaningful) clinical benefit. Patients with MSS and proficient mismatch repair tumors and those without liver metastasis benefited more
versus regorafenib
	atezolizumab alone
	IMblaze-370 (A ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab monotherapy	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	90 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)
	atezolizumab plus cometinib
	IMblaze-370 (AC ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab plus cometinib	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	183 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)

metastatic/advanced - colorectal cancer (mCRC) metastatic/advanced - colorectal cancer (mCRC)

mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)